(13223324), S. R. M., (22676321), A. R., (22676324), M. A. P., (22676327), E. Z. E., (22676330), M. D., (3480455), H. H., . . . (22676354), M. J. Y. A. (2025). Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
Chicago Style (17th ed.) Citation(13223324), Seyed Reza Mousavi, et al. Adverse Events During Follow-up Period in Phase III Non-inferiority Clinical Trial of SnaFab Compared to Razi Antivenom in Snakebites. 2025.
MLA (9th ed.) Citation(13223324), Seyed Reza Mousavi, et al. Adverse Events During Follow-up Period in Phase III Non-inferiority Clinical Trial of SnaFab Compared to Razi Antivenom in Snakebites. 2025.
Warning: These citations may not always be 100% accurate.